Cargando…
MIR29B mediates epigenetic mechanisms of HBG gene activation
Sickle cell disease (SCD) affects over 2 million people worldwide with high morbidity and mortality in underdeveloped countries. Therapeutic interventions aimed at reactivating fetal haemoglobin (HbF) is an effective approach for improving survival and ameliorating the clinical severity of SCD. A cl...
Autores principales: | Starlard‐Davenport, Athena, Smith, Alana, Vu, Luan, Li, Biaoru, Pace, Betty S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589104/ https://www.ncbi.nlm.nih.gov/pubmed/30891745 http://dx.doi.org/10.1111/bjh.15870 |
Ejemplares similares
-
Targeting Genetic Modifiers of HBG Gene Expression in Sickle Cell Disease: The miRNA Option
por: Starlard-Davenport, Athena, et al.
Publicado: (2022) -
Heterozygosity for bisphosphoglycerate mutase deficiency expressing clinically as congenital erythrocytosis: A case series and literature review
por: van Dijk, Myrthe J., et al.
Publicado: (2022) -
MicroRNA29B induces fetal hemoglobin via inhibition of the HBG repressor protein MYB in vitro and in humanized sickle cell mice
por: Gu, Qingqing, et al.
Publicado: (2022) -
Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia
por: Kumkhaek, Chutima, et al.
Publicado: (2008) -
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease
por: Vichinsky, Elliott, et al.
Publicado: (2007)